| 2024-12-10 |
Week 2, December 2024: Inflammatory Conditions |
| 2024-10-08 |
Week 2, October 2024: ADCs in Regulatory Review |
| 2024-09-10 |
Week 2, September 2024: Non-Small Cell Lung Cancer |
| 2024-08-30 |
In Vivo vs. In Vitro: Understanding the Differences |
| 2024-08-01 |
July 2024: Paroxysmal nocturnal hemoglobinuria (PNH) |
| 2024-07-16 |
Week 3, July 2024: Immunostimulatory ADCs (iADCs) |
| 2024-07-03 |
Week 1, July 2024: Blood Disorders |
| 2024-06-18 |
Week 3, June 2024: Intravenous Immunoglobulin Therapy |
| 2024-05-30 |
May 2024: The Ozempic Craze: In the Perspective of Antibody Drugs |
| 2024-05-21 |
Week 3, May 2024: A Continued Look at the Progress of COVID Therapies |
| 2024-04-11 |
Week 2, Apr 2024: Cancer Research Trends at AACR |
| 2024-04-02 |
Week 1, Apr 2024: The Complexities of Drug Approvals |
| 2024-04-01 |
March 2024: Organ Transplantation |
| 2024-03-26 |
Week 3, Mar 2024: Organ Transplantation |
| 2024-02-20 |
Week 3, Feb 2024: Antibody Agonists |
| 2024-02-14 |
Week 2, Feb 2024: Combination Therapies |
| 2024-02-07 |
Week 1, Feb 2024: Challenging Multiple Myeloma |
